Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Current Assets
Cash and cash equivalents	$ 334.0	$ 474.8
Accounts receivable, net of allowances of $6.2 (2019) and $8.4 (2018)	816.9	651.8
Other receivables	73.0	57.6
Inventories (Note 8)	1,050.7	1,004.1
Prepaid expenses and other	87.4	113.9
Restricted cash (Note 20)	11.1	202.7
Total current assets	2,373.1	2,504.9
Noncurrent Assets
Goodwill (Note 11)	2,989.6	2,958.0
Other intangibles, net (Note 11)	2,482.8	2,504.8
Other noncurrent assets	185.0	66.6
Property and equipment, net (Note 12)	955.3	922.4
Total assets	8,985.8	8,956.7
Current Liabilities
Accounts payable	222.6	205.2
Employee compensation	99.6	98.9
Sales rebates and discounts	211.0	169.9
Current portion of long term debt (Note 9)	24.5	29.0
Other current liabilities	244.4	199.0
Payable to Lilly (Note 20)	16.4	268.7
Total current liabilities	818.5	970.7
Noncurrent Liabilities
Long-term debt (Note 9)	2,330.5	2,443.3
Accrued retirement benefits (Note 18)	82.5	109.1
Deferred taxes (Note 15)	100.8	114.6
Other noncurrent liabilities	106.6	121.5
Total liabilities	3,438.9	3,759.2
Commitments and Contingencies (Note 16)
Equity
Preferred stock, 1,000,000,000 shares authorized, no par value; none issued	0.0	0.0
Common stock, 5,000,000,000 shares authorized, no par value; 373,011,513 and 365,643,911 shares issued and outstanding as of December 31, 2019 and 2018, respectively	0.0	0.0
Additional paid-in capital	5,636.3	5,403.3
Retained earnings	84.3	16.4
Accumulated other comprehensive loss	(173.7)	(222.2)
Total equity	5,546.9	5,197.5
Total liabilities and equity	$ 8,985.8	$ 8,956.7